The Global Game Changers from Biotech Industry


Forbes has released its inaugural edition of ‘Global Game Changers’ for the year 2016 and included 30 global business leaders. This list was ranked based on the brilliance of the their ideas and the audacity of their ambition (as said by senior editor Steve Schaefer, Forbes). In this wide domain of leaders who have outshined in their zone, we zoomed into the elite personalities of the biotech industries who received this eminent position in Forbes by their prominent efforts towards elevating the innovation and technology of the biotech world and touched the lives of people for their betterment.


 1. Katrine Bosley


Current Company: Editas Medicine Inc.

Title: CEO

Forbes Rank: 5

Location: Cambridge, Massachusetts

Age: 48

Salary: $386,200

Katrine Bosley is the CEO of Editas and is a global game changer

How a Global Game Changers?

A Biology graduate from Cornell University with initial experiences in business development and venture capitalist (completed Program for Management Development at Harvard Business School), Ms. Bosley is currently the Chief Executive Officer and President of Cambridge, Massachusetts, USA based Editas Medicine Inc., which is a gene editing (CRISPR) company for therapeutics discoveries. In January, 2016, Editas became the first gene editing company to file for initial public offering (IPO) with up to $100 million in stock. She was first CEO of Avila Therapeutics (Massachusetts, United States, now a Celgene company), Vice President of Business Development and Vice President of Strategic Operations at Adnexus Therapeutics (another Massachusetts based biotechnology company, formerly Compound Therapeutics, Inc. and now a Bristol-Myers Squibb company). She was also holding several key positions in Biogen Idec (led the deal between Biogen and Elan Pharmaceuticals for Antegren (natalizumab), Alkermes and analyst for Highland Capital Partners (a venture capital firm). Since August, 2013, she has been chairman of Genocea Biosciences, Inc. (Cambridge, Massachusetts, United States based biotechnology company). Since March, 2013, she has been serving as an Independent Non-Executive Director at Galapagos NV (Belgian pharmaceutical research company). She also serves as a Director of Scholar Rock, Inc., and Coco Therapeutics. Ms. Bosley is also the Entrepreneur-in-Residence at The Broad Institute


2. Jay Flatley

Current Company: Illumina, Inc.

Title:  Chairman and CEO

Forbes Rank: 8

Location: San Diego , California , United States

Age: 62

Salary: $995,693

Jay Flatley is CEO of Illumina Inc and is Global Game ChangerHow a Global Game Changers?

Jay T. Flatley has been associated with Illumina since 1999 and currently holds the position of Chairman of the Board of Directors and CEO. He is also in the Board of Directors for two Illumina subsidiaries-Helix and Grail, Advisory Board member for UC San Diego’s Moore Cancer Center and in the Board of Directors at Coherent and Denali. He has received B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University. He has catapulted the sales of the company from $1.3 million in 2000 to $2.2 billion in 2015 which shows a significant compound annual growth rate of 64 percent. By the acquisition of Solexa in 2006, he drove the expansion of the company from microarrays to next-generation sequencing. He was also the Co-Founder of Molecular Dynamics, Inc. (now a part of GE healthcare) in which he directed the development and launch of over 15 major instrumentation systems (one among this was the world’s first capillary-based DNA sequencer). He also served as Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company and as Executive Vice President in Manning Technologies as well as held various manufacturing positions for the Autolab division of Spectra Physics. Illumina has been included in Forbes 25 Fastest-Growing Tech Companies, Fortune 100 Fastest-Growing Companies, Deloitte and Touche Fast 50 and Fast 500 lists various times and as the World’s Smartest Company by MIT Technology Review in 2014.


3. Dr. Osman Kibar, PhD

Current Company: Samumed, LLC

Title:  Co-founder and CEO

Forbes Rank: 16

Location: San Diego , California , United States

Age: 45

Salary: unknown

Osman Kibar is CEO of Samumed and is Global Game ChangerHow a Global Game Changers?

A graduate (B.A.) in Mathematical Economics from Pomona College (California, USA) and B.S. in Electrical Engineering from California Institute of Technology, USA and a M.S. and a Ph.D. in Electrical Engineering (Applied Physics) from the University of California, San Diego, USA, Dr. Kibar co-founded Samumed, LLC in 2007 and since then he serves as the Chief Executive Officer. Samumed is a global leader in tissue regeneration and valued $12 million. In November, 2015, Samumed announced successful completion of its Phase II clinical trials by its experimental drug SM04554 and declared it as a potential treatment of androgenetic alopecia (AGA, male pattern baldness). Regrowing bald men’s hair! Definitely a game changer.

Dr. Kibar also serves as Chief Executive Officer of Epitherix, LLC and Vice President at FirstMark Capital, LLC. Through Pequot venture and private equity funds, he focus on investments in infrastructure and healthcare technologies. He was also a founder of Genoptix, a company specialize in oncology diagnostics and informatics services using optical technology and was acquired by Novartis for $470 million in 2011. He was also the co-founder of E-tenna Corporation, an antenna developer for commercial wireless applications. Other than business, Dr. Kibar is a professional researcher at the University of California, San Diego, USA. He was also the Co-founder of an integrated logistics solutions provider company known as Dynamic Connections and Orimedix LLC (a R&D laboratory).


4. Dr. John F. Milligan, PhD

Current Company: Gilead Sciences

Title:  Co-founder and CEO

Forbes Rank: 20

Location: Foster City, California, United States

Age: 55

Salary: $1,046,898

John F. Milligan Gilead CEOHow a Global Game Changers?

Dr.John F. Milligan held the position of CEO in Gilead Sciences in March 2016 and its President in May 2008. He was in the position of Chief Operating Officer at Gilead Sciences from March 2007- March 2016. He also served as the Chief Financial Officer from January 2008-May 2008. He joined Gilead in 1990 as Research Scientist and since then held several positions in the company. He is in the boards of Biotechnology Industry Organisation (BIO) and also a trustee of Ohio Wesleyan University. Dr. Milligan completed his B.A. from Ohio Wesleyan University. From the University of Illinois at Urbana–Champaign, he received his PhD in Biochemistry then worked as an American Cancer postdoctoral fellow at the University of California at San Francisco. Dr. Milligan was accoladed as “Bay Area CFO of the Year” in 2006 for companies with revenues greater than $500 million. Since 1996, he was in the role of Director of Project Management and Project Team Leader for Gilead and Hoffmann-La Roche collaboration on Tamiflu®. Then he turned to Corporate Development of Gilead in 1998 and served as Vice President Corporate Development with the high profile duty of licensing, corporate partnerships, mergers and acquisitions since 2000. In 2006 and 2007, Institutional Investor magazine acknowledged him as the top biotechnology industry CFO in the U.S. He also served as the Director of Pharmasset, Inc., since January 2012 and Pacific Biosciences of California, Inc., since July 2013 .


5. Dr. Peder Holk Nielsen, PhD

Current Company: Novozymes

Title:  President and CEO

Forbes Rank: 22

Location: Bagsværd, Denmark

Age: 60

Salary: kr20,400,000

Peder Holk Nielsen CEO NovozymesHow a Global Game Changers?

A graduate in commerce (B. Com) in International Business Management from Copenhagen Business School and a Ph.D. and an M.Sc. in Chemical Engineering from the Technical University of Denmark (DTU), Dr. Nielsen began his career as as a Product Manager in the Enzymes Division of Novo A/S in 1984. He took took over as the second CEO of Novozymes, after IPO filing of company. He also served as the Corporate Vice president for Enzyme Development & Industrial Biotechnology at Novo Nordisk. From 2007 to April 1, 2013, he was Executive Vice President of Enzyme Business at Novozymes A/S and also served as an Head of Enzymes Business at Novozymes A/S. Dr. Nielsen also served as an Executive Vice President of Sales & Marketing at Novozymes A/S. He also served on the Board of Directors of Hempel A/S (a leading coatings developer and supplier company), Hempel (China) Ltd and LEO Pharma A/S (a leading multinational Danish pharmaceutical company for dermatological and thrombotic treatments). Other than that, Dr. Nielsen also served a as Member of Advisory Board at Center for Biocatalysis and Bioprocessing. According to an estimate of 2013, Novozymes holds 48% of the global enzyme market which make it the world’s largest producer of industrial enzymes and which in turn make Dr. Nielsen a Global Game Changers.


5. Dr. Cyrus S. Poonawalla

Current Company: Serum Institute of India

Title:  Founder, President and CEO

Forbes Rank: 26

Location: Pune, India

Age: 71

Net Worth: $8.5 billion

cyrus poonawalla Serum Institute of IndiaHow a Global Game Changers?

A graduate in commerce (B. Com) from Brihan Maharashtra College of Commerce, University of Pune in 1966, Dr. Poonawalla Co-Founded Serum Institute of India Ltd at the age of 25. Ever since he is known as the India’s vaccine king as his company became the largest producers of vaccines in the world (according to the number of doses). The renowned products of the company include Nasovac-S, Poliovac and Tresivac. Dr. Poonawalla serves as the Managing Director of Serum Institute of India Ltd and as Chairman of Serum Institute of India Limited and Poonawalla Investment & Industries Pvt.Ltd. Serum Institute of India is also developing an intra-nasal swine flu vaccine. In March 2016, Forbes ranked him as the #5th richest person in India and #133th richest person in the world. In 2005, Government of India awarded him with the honour of Padma Shri (fourth highest civilian award in the Republic of India) for his contribution to the field of medicine.


Liked this review? Subscribes to our newsletter and read similar articles.

or you can visit our review archive here


Co-author and Editor: Tiash Saha

Tiash saha is editor of

Leave a reply

Your email address will not be published. Required fields are marked *